Methylenedioxyphentermine

Methylenedioxyphentermine (MDPH) is a lesser-known psychedelic drug. MDPH was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines I Have Known and Loved), the minimum dosage is listed as 160 mg, and the duration unknown. MDPH produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH.

History

MDPH was first synthesized and documented by Alexander Shulgin, a renowned American medicinal chemist and psychopharmacologist. Shulgin's pioneering work in the study of psychedelic drugs led to the discovery and synthesis of many novel substances, including MDPH.

Chemistry

MDPH is a substituted amphetamine, which means it is a derivative of the parent compound amphetamine. It is structurally related to other psychedelic amphetamines such as MDMA (Ecstasy) and Mescaline. The methylenedioxy group in MDPH is responsible for its classification as a methylenedioxyphenethylamine.

Pharmacology

The pharmacological properties of MDPH are not well-studied. As a psychedelic amphetamine, it is presumed to act as a serotonin releasing agent and possibly as a monoamine oxidase inhibitor (MAOI). However, these mechanisms of action are speculative and have not been empirically confirmed.

Legal Status

The legal status of MDPH varies by country. In the United States, it is not specifically listed as a controlled substance, but it could potentially be considered an analog of other controlled substances under the Federal Analogue Act.

See Also

• Phenethylamine
• Psychedelic drug
• Alexander Shulgin
• PiHKAL

‎ Template:Pharmaceutical-stub